Human Genome Sciences, Inc. Announces Submission of Marketing Authorization Application to European Medicines Evaluation Agency for BENLYSTA(R) (Belimumab)

ROCKVILLE, Md.--(BUSINESS WIRE)--Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that GlaxoSmithKline (GSK) has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for approval to market BENLYSTA® (belimumab) for the treatment of systemic lupus erythematosus (SLE).